Novelties in Ovarian Cancer Research and Treatment

Speaker: Nicoletta Colombo

N. Colombo explains the findings presented at ECC 2015 from the ROSiA study of extended duration of front-line bevacizumab-based therapy; analysis from the AURELIA trial on sensitivity of CT vs CA125 in detecting disease progression; and risk of disease relapse in ovary in case of fertility preserving surgery in ovarian cancer patients.

Discussion Points

  • Abstract #2702 from ECC 2015: Safety and efficacy in ROSiA, a single-arm study of extended duration front-line bevacizumab-containing therapy in 1021 women with ovarian cancer. What is a rationale for the study? What are the key study results? What is the impact for current practice?
  • Abstract #2703 from ECC 2015: Computed tomography is more sensitive than CA 125 in detecting disease progression in patients with platinum-resistant ovarian cancer: Analysis of the AURELIA trial. What is a rationale for the study? What are the key study results? What is the impact for current practice?
  • Abstract #2704 from ECC 2015: Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer: Results of an international multicenter study comprising 545 patients. What is a rationale for the study? What are the key study results? What is the impact for current practice?